MIIST305: GI damage relief
Synedgen’s MIIST platform has been developed with extensive funding from the U.S. Army, DARPA, and other partners. This technology has been applied extensively to develop products that meet warfighter needs in combat injuries. Synedgen is developing the next generation of these cutting-edge products for injury to the gut mucosal surface.
Synedgen is developing MIIST305, the only non-steroidal and non-biologic drug that addresses underlying damage to the gut tissue and promotes regeneration. This drug has the potential to immediately impact patients with ulcerative colitis (UC) and in radiation injury, conditions in which the compromised mucosal barrier behaves as a wound to the intestinal surface, propagating inflammation and infection.